The Alliance for Regenerative Medicine publishes a cross-border healthcare plan, which would enable ‘timely and effective’ access to ATMPs for patients in Europe.
Early dialogue with patients is ‘critical’ to design efficient clinical development programs for ATMPs and avoid ‘data gaps’, an executive from ARM says.
In a significant move at the larger end of the biopharma world, AstraZeneca’s global VP of cardiovascular, renal and metabolism made the move to Novo Nordisk to head up its biopharm unit.
